أعرض في EDS

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151

التفاصيل البيبلوغرافية
العنوان: Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
المؤلفون: Constanze Kaiser, Frede Donskov, Michael B. Atkins, Toni K. Choueiri, U. De Giorgi, Lawrence Fong, Tarik Khaznadar, David F. McDermott, Brian I. Rini, Darren Tayama, F. Di Nucci, Robert J. Motzer, Yulei Wang, Bernard Escudier, Sumanta K. Pal, Thomas Powles, Cristina Suarez
المصدر: Annals of Oncology. 29:viii308
بيانات النشر: Elsevier BV, 2018.
سنة النشر: 2018
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Bevacizumab, business.industry, Sunitinib, Hematology, medicine.disease, Pooled analysis, Tolerability, Atezolizumab, Renal cell carcinoma, Internal medicine, medicine, business, medicine.drug
تدمد: 0923-7534
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::fd18d083c9cdc5d6bc8d41b0d4789202Test
https://doi.org/10.1093/annonc/mdy283.082Test
حقوق: OPEN
رقم الانضمام: edsair.doi...........fd18d083c9cdc5d6bc8d41b0d4789202
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534